 |
|
A Controlled Trial of HA-1A in a Canine Model of Gram-negative Septic Shock
Zenaide M. N. Quezado, MD;
Charles Natanson, MD;
David W. Ailing, MD, PhD;
Steven M. Banks, PhD;
Cezar A. Koev, MD;
Ronald J. Elin, MD, PhD;
Jeanette M. Hosseini;
John D. Bacher, VMD;
Robert L. Danner, MD;
William D. Hoffman, MD
JAMA. 1993;269(17):2221-2227.
Abstract
| |
Objectvie.
—To investigate the therapeutic efficacy and microbiological and physiological effects of a human IgM monoclonal antibody (HA-1 A) directed against the lipid A component of endotoxin in a canine model of sepsis that simulates the cardiovascular abnormalities of human septic shock.
Design.
—Blinded, placebo-controlled 28-day trial.
Interventions.
—Purpose-bred beagles were implanted with an intraperitoneal clot infected with Escherichia coli O111:B4. At clot placement, animals received HA-1A (10 mg.kg-1), control human IgM antibody (10 mg.kg-1), or control human serum albumin intravenously. All animals were given antibiotic and fluid therapy.
Measures.
—Survival and microbiological and physiological events.
Results.
—Only two (15%) of 13 animals in the HA-1A group, compared with eight (57%) of 14 control animals (combined control human IgM antibody and control human serum albumin groups) (P=.05), survived 28 days. At 24 hours, the HA-1A group had lower mean arterial pressure (P=.04) and cardiac index (P=.004) and higher lactate levels (P=.05) compared with the combined-controls group. In addition, these parameters in the HA-1A group were significantly more predictive of death. The HA-1 A and combined-controls groups had similar significant increases in the level of endotoxemia and bacteremia. Studies of toxic effects showed no harmful effects of control human IgM antibody in infected animals or HA-1 A in noninfected animals.
Conclusion.
—In a canine model of E coli sepsis, HA-1 A did not alter levels of bacteremia or endotoxemia and actually decreased survival. If these data are relevant to human septic shock, HA-1 A therapy should be limited until the conditions under which this monoclonal antibody has beneficial or deleterious effects are more completely defined.
(JAMA. 1993;269:2221-2227)
Author Affiliations
From the Department of Critical Care Medicine (Drs Quezado, Natanson, Alling, Banks, Koev, Danner, and Hoffman), Department of Clinical Pathology (Dr Elin and Ms Hosseini), and the Veterinary Resources Program, National Center for Research Resources (Dr Bacher), National Institutes of Health, Bethesda, Md.
Footnotes
Preliminary data were published in abstract form in Clinical Research. 1992;40:286.
Reprint requests to Department of Critical Care Medicine, National Institutes of Health, Bldg 10, Room 7D43, 9000 Rockville Pike, Bethesda, MD 20892 (Dr Quezado).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Apoptotic Cells Protect Mice against Lipopolysaccharide-Induced Shock
Ren et al.
J. Immunol. 2008;180:4978-4985.
ABSTRACT
| FULL TEXT
A canine model of septic shock: balancing animal welfare and scientific relevance
Minneci et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H2487-H2500.
ABSTRACT
| FULL TEXT
Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein
Alexander et al.
Blood 2004;103:93-99.
ABSTRACT
| FULL TEXT
Anti-Lipid A Monoclonal Antibody Centoxin (HA-1A) Binds to a Wide Variety of Hydrophobic Ligands
Helmerhorst et al.
Infect. Immun. 1998;66:870-873.
ABSTRACT
| FULL TEXT
Relationship of Preoperative Antiendotoxin Core Antibodies and Adverse Outcomes Following Cardiac Surgery
Bennett-Guerrero et al.
JAMA 1997;277:646-650.
ABSTRACT
Review: Bacterial endotoxin and the human monoclonal antibody HA-IA: specificity, potential mechanisms of action, and limits to its effectiveness
Lagrange et al.
Innate Immunity 1995;2:371-386.
ABSTRACT
Looking Back on HA-1A
Quezado et al.
Arch Intern Med 1994;154:2393-2393.
ABSTRACT
The French National Registry of HA-1A (Centoxin) in Septic Shock: A Cohort Study of 600 Patients
The National Committee for the Evaluation of Cento
Arch Intern Med 1994;154:2484-2491.
ABSTRACT
Projected Impact of Monoclonal Anti-Endotoxin Antibody Therapy
Bates and Lee
Arch Intern Med 1994;154:1241-1249.
ABSTRACT
Minireview: Therapeutic intervention in sepsis with antibody to endotoxin: is there a future?
Cross and Opal
Innate Immunity 1994;1:57-69.
ABSTRACT
MORE EVIDENCE AGAINST THE EFFECTIVENESS OF HA-1A
JWatch General 1993;1993:7-7.
FULL TEXT
The Search for a Magic Bullet to Fight Sepsis
Bone
JAMA 1993;269:2266-2267.
ABSTRACT
|
